Notification That Annual Report Will Be Submitted Late (nt 10-k)

Date : 04/02/2019 @ 8:30PM
Source : Edgar (US Regulatory)
Stock : Inspyr Therapeutics Inc (PK) (NSPX)
Quote : 0.0035  0.0 (0.00%) @ 9:05PM

Notification That Annual Report Will Be Submitted Late (nt 10-k)




Washington, D.C. 20549


FORM 12b-25


SEC File Number




(Check One) : ☒  Form 10-K   ☐ Form 20-F   ☐ Form 11-K   ☐ Form 10-Q   ☐ Form 10-D   ☐ Form N-SAR    ☐ Form N-CSR

For Period Ended: December 31, 2018                                 


☐   Transition Report on Form 10-K

☐   Transition Report on Form 20-F

☐   Transition Report on Form 11-K

☐   Transition Report on Form 10-Q

☐   Transition Report on Form N-SAR

For the Transition Period Ended: ________________________


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:




Inspyr Therapeutics, Inc.  


Full Name of Registrant


GenSpera, Inc. 


Former Name if Applicable


31200 Via Colinas #200  


Address of Principal Executive Office (Street and Number)


Westlake Village, CA 91362  


City, State and Zip Code


PART II -- RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)


  (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;


(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form  20-F, Form 11-K, Form N-SAR or Form  N-CSR, or portion thereof, will be filed  on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the  prescribed due date; and
  (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.







State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)


The compilation, dissemination and review of the information required to be presented in the Form 10-K for the period ending December 31, 2018 could not be completed and filed by April 1, 2018, without undue hardship and expense to the registrant. The registrant anticipates that it will file its Form 10-K for the period ended December 31, 2016 within the "grace" period provided by Securities Exchange Act Rule 12b-25.




(1) Name and telephone number of person to contact in regard to this notification


Christopher Lowe   (818)   597-7522
(Name)   (Area Code)   (Telephone Number)


(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). 

☐  Yes ☒  No


Form 10-K for the year ending December 31, 2017 and Forms 10-Q for the Quarters ending March 31, 2018, June 30, 2018 and September 30, 2018 have not been filed as of the date hereof.


(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒  No


If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




  Inspyr Therapeutics, Inc.  
  (Name of Registrant as Specified in Charter)  

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.


Date   April 2, 2018   By /s/  Christopher Lowe  
        Christopher Lowe  
        Chief Executive Officer  



Inspyr Therapeutics (PK) (USOTC:NSPX)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Inspyr Therapeutics (PK) Charts.

Inspyr Therapeutics (PK) (USOTC:NSPX)
Intraday Stock Chart

Today : Tuesday 18 February 2020

Click Here for more Inspyr Therapeutics (PK) Charts.

Latest NSPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.